Edition:
United Kingdom

FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD


Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD.‍otsuka Pharmaceutical - FDA accepts Otsuka's resubmission to support a regulatory review of tolvaptan in treatment of adpkd​.Otsuka Holdings Co Ltd - ‍April 2018 is anticipated completion timing of FDA's review based on PDUFA timeline ​.